RUNX1 and acute myeloid leukemia: In another study, the potential of RUNX1 mutations as MRD marker was investigated using deep amplicon sequencing in a prospective cohort of 814 AML patients, with 103 patients eligible for RUNX1 paired diagnosis-remission analysis.